JD HEALTH
06618
BIDU-SW
09888
JD-SW
09618
NTES-S
09999
TRIP.COM-S
09961
(Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q3)Mar 31, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 52.16%8.85B | 141.68%3.49B | 35.22%16.75B | 14.40%5.81B | -27.58%1.44B | 295.41%12.38B | --5.08B | 616.35%1.99B | 396.13%3.13B | --278.05M |
Operating income | 52.16%8.85B | 141.68%3.49B | 35.22%16.75B | 14.40%5.81B | -27.58%1.44B | 295.41%12.38B | 5.08B | 616.35%1.99B | 396.13%3.13B | 278.05M |
Cost of sales | -42.09%-8.75B | -127.24%-3.53B | -16.58%-16.67B | 3.84%-6.15B | 38.32%-1.56B | -216.30%-14.3B | ---6.4B | -506.88%-2.52B | -375.31%-4.52B | ---415.46M |
Operating expenses | -42.09%-8.75B | -16.58%-16.67B | 3.84%-6.15B | -216.30%-14.3B | -6.4B | -375.31%-4.52B | -415.46M | |||
Gross profit | 129.33%100.23M | 104.21%80.47M | 74.09%-341.76M | -37.74%-1.91B | -1.32B | -334.18%-1.39B | -137.41M | |||
Selling expenses | -10.02%-902.65M | -8.83%-427.9M | -61.21%-1.8B | -105.51%-820.45M | -142.12%-393.2M | -160.27%-1.11B | ---399.22M | -80.99%-162.4M | -176.18%-427.86M | ---89.73M |
Administrative expenses | -9.99%-435.02M | 22.91%-139.3M | -1.83%-857.51M | -28.53%-395.52M | -17.26%-180.7M | -111.42%-842.1M | ---307.72M | -82.65%-154.1M | -116.70%-398.31M | ---84.37M |
Research and development expenses | -48.37%-1.22B | -26.09%-520M | -36.09%-1.92B | -56.37%-823.16M | -70.06%-412.4M | -90.62%-1.41B | ---526.41M | -160.76%-242.5M | -155.84%-740.02M | ---93M |
Impairment and provision | -144.14%-354K | ---- | 101.40%25K | 186.80%802K | ---- | -501.01%-1.79M | ---924K | ---- | -40.57%-298K | ---95K |
-Other impairment is provision | -144.14%-354K | ---- | 101.40%25K | 186.80%802K | ---- | -501.01%-1.79M | ---924K | ---- | -40.57%-298K | ---95K |
Special items of operating profit | 37.69%64.05M | ---- | 117.67%114.58M | -21.94%46.52M | ---- | -38.65%52.64M | --59.59M | ---- | 9.62%85.79M | --6.48M |
Operating profit | -2.63%-2.4B | 2.86%-1.13B | 16.25%-4.38B | 6.41%-2.33B | -8.17%-1.16B | -82.23%-5.23B | -2.49B | -169.27%-1.07B | -229.87%-2.87B | -398.12M |
Financing income | 135.47%211.87M | ---- | 60.09%229.36M | 56.01%89.98M | ---- | 70.55%143.27M | --57.67M | ---- | 6,392.04%84.01M | --13.2M |
Financing cost | 35.57%-22.74M | ---- | -95.12%-72.22M | -194.94%-35.29M | ---- | 39.97%-37.01M | ---11.97M | ---- | 73.23%-61.66M | ---11.46M |
Share of profits of associates | -305.77%-5.82M | ---- | -65.08%4.09M | -26.78%2.83M | ---- | 5,871.94%11.71M | --3.86M | ---- | 112.84%196K | ---854K |
Earning before tax | 2.83%-2.21B | 17.47%-4.22B | 6.87%-2.28B | -79.52%-5.11B | -2.44B | -158.68%-2.85B | -397.24M | |||
Tax | 65.96%-16K | ---- | -58.33%-76K | ---47K | ---- | ---48K | ---- | ---- | ---- | ---- |
After-tax profit from continuing operations | 2.83%-2.21B | 17.47%-4.22B | 6.87%-2.28B | -79.53%-5.11B | -2.44B | -158.68%-2.85B | -397.24M | |||
Earning after tax | 2.83%-2.21B | 17.47%-4.22B | 6.87%-2.28B | -79.53%-5.11B | -2.44B | -158.68%-2.85B | -397.24M | |||
Profit attributable to shareholders | 2.83%-2.21B | 10.60%-1.01B | 17.47%-4.22B | 6.87%-2.28B | -8.71%-1.13B | -79.53%-5.11B | -2.44B | -162.36%-1.04B | -158.68%-2.85B | -397.24M |
Basic earnings per share | 17.09%-1.65 | 25.97%-3.62 | 17.77%-1.99 | -61.39%-4.89 | -2.42 | -1.34%-3.03 | -0.57 | |||
Diluted earnings per share | 17.09%-1.65 | 25.97%-3.62 | 17.77%-1.99 | -61.39%-4.89 | -2.42 | -1.34%-3.03 | -0.57 | |||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- |
Auditor | -- | -- | PricewaterhouseCoopers | -- | -- | PricewaterhouseCoopers | -- | -- | PricewaterhouseCoopers | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.